Addus Homecare Corp ADUS

Health CareHealthcare Providers & ServicesUnited States of America

Last close 125.75 USD on Nov 2, 2026, +17.1% year to date

Quant rating

Quant rating A Rank 37 of 565 in Health Care

Growth B 152 of 565
Valuation A 71 of 565
Quality A 38 of 565
Revisions B 132 of 565
Momentum B 169 of 565

Wall Street consensus Buy (2.00)Average target 134.08 USD +6.6%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 2.3B
Enterprise value: 2.3B
52-week range: 88.03 – 126.95
3-year range: 82.05 – 135.92
Dividend yield: –
Beta (5 years): 0.74
Shares outstanding: 18.7M
Next earnings: Nov 3, 2026

About the company

Addus HomeCare Corporation is engaged in providing home care services. Its segments include Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. The services it provides include assistance with bathing, grooming, feeding and dressing, medication reminders and others. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and related services for their families. The Hospice services it provides include palliative nursing care, social work, spiritual counseling, homemaker services and bereavement counseling. Its Home Health segment provides services that are medical in nature to individuals who may require assistance during an illness or after hospitalization and includes skilled nursing and physical, occupational and speech therapy.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	1,423	1,155	1,059	951	864	–
Revenue growth	23.2%	9.1%	11.3%	10.0%	13.0%	13.2%
EPS (basic, normalized)	6.23	5.26	4.58	3.73	3.63	–
EPS growth	18.4%	14.8%	22.8%	2.8%	–	–
Gross margin	32.5%	32.5%	32.3%	32.5%	31.2%	32.2%
Net margin	6.7%	6.4%	5.9%	4.8%	5.2%	5.8%
ROE	9.3%	8.8%	9.3%	7.6%	8.3%	8.7%

Balance sheet, last quarter
Cash & short-term investments (mil)	99.6
Current ratio	1.69x
Long-term debt (mil)	61.6
Net debt (mil)	−38.0
Total equity (mil)	1,148
Net debt / equity	−0.03x
Net debt / EBITDA	−0.21x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	1,423	+23.2%	1.6x	180	+29.0%	12.8x	6.23	+18.4%	20.2x
2026	1,525	+7.2%	1.5x	197	+9.4%	11.7x	7.06	+13.3%	17.8x
2027	1,615	+6.0%	1.4x	210	+6.9%	11.0x	7.56	+7.1%	16.6x
2028	1,705	+5.5%	1.4x	223	+5.9%	10.4x	8.00	+5.9%	15.7x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,525	0.0%	+0.1%	+0.3%	7.06	0.0%	+0.2%	+1.4%
2027	1,615	+1.0%	+1.0%	+1.5%	7.56	+0.4%	+0.5%	+1.1%
2028	1,705	+1.7%	+1.8%	+2.5%	8.00	+0.8%	+0.9%	+1.3%

Earnings surprises EPS beat in 4 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	281	287	290	297	338	349	362	373	364	377
Sales mean (mil)	280	285	289	292	340	347	354	372	366	376
Surprise	+0.4%	+0.7%	+0.1%	+1.9%	−0.6%	+0.8%	+2.2%	+0.2%	−0.7%	+0.3%
EPS reported	1.21	1.35	1.30	1.38	1.42	1.49	1.56	1.77	1.62	1.73
EPS mean	1.09	1.21	1.28	1.35	1.33	1.47	1.53	1.72	1.55	1.70
Surprise	+11.0%	+11.2%	+1.3%	+2.5%	+6.5%	+1.4%	+1.7%	+2.6%	+4.5%	+1.8%

Peer comparison Healthcare Providers & Services

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
ADUS Addus Homecare Corp	2.3B	−0.21x	6.7%	2.05x	17.8x	16.6x	11.7x	11.0x
UNH UnitedHealth Group Incorporated	359.4B	–	2.7%	3.45x	19.4x	17.1x	13.1x	11.9x
CVS CVS Health Corporation	113.2B	2.50x	0.4%	1.42x	11.0x	10.4x	8.3x	7.9x
HCA HCA Healthcare, Inc.	97.7B	3.41x	9.0%	−12.21x	15.6x	14.9x	9.5x	9.4x
ELV Elevance Health Inc	89.4B	–	2.8%	2.00x	14.2x	13.7x	10.0x	10.3x
CI The Cigna Group	78.0B	2.49x	2.2%	1.83x	9.7x	8.8x	7.7x	7.2x
Mean		2.05x	4.0%	−0.24x	14.6x	13.6x	10.1x	9.6x
Median		2.50x	2.8%	1.91x	14.9x	14.3x	9.7x	9.8x

Technical analysis

1M+13.0%
3M+8.9%
1Y+7.6%
3Y+53.2%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Addus Homecare Corp, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	1,423	1,155	1,059	951	864	765
Cost of revenue	961	780	717	642	595	540
Gross profit	462	375	342	309	270	225
Selling, general & administrative expenses	307	254	235	217	182	162
Research & development	–	–	–	–	–	–
Depreciation/amortization	16.4	13.5	14.1	14.1	14.5	12.1
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	0	5.0	1.7	9.0	7.3	5.8
Other operating expenses	0	0	0	0	0	0
Operating income	139	103	91.0	68.7	65.9	44.5
Net interest income (expense)	−11.2	−3.3	−9.6	−8.6	−5.5	−2.6
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	127	99.4	81.3	60.2	60.4	41.9
Provision for taxes	31.5	25.8	18.8	14.1	15.3	8.8
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	95.9	73.6	62.5	46.0	45.1	33.1
Extraordinary items	–	–	–	–	0	–
Net income	95.9	73.6	62.5	46.0	45.1	33.1
EBIT, normalized	149	119	99.1	85.8	74.3	55.9
EBITDA, normalized	165	132	113	99.9	88.8	68.0
Basic EPS, normalized	6.23	5.26	4.58	3.73	3.63	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Addus Homecare Corp, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	81.6	98.9	64.8	80.0	169	145
Receivables	163	135	116	126	146	135
Total inventory	–	–	–	–	–	–
Prepaid expenses	17.8	18.4	16.9	11.0	6.9	3.4
Other current assets	7.4	7.8	2.2	5.7	2.5	4.7
Total current assets	269	260	200	223	324	288
Property, plant & equipment	68.7	72.1	69.4	60.2	54.5	57.7
Goodwill	997	971	663	583	504	469
Intangibles	102	110	92.0	72.2	64.3	71.5
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	0	0	0	0	0	6.5
Total assets	1,437	1,413	1,024	938	948	893
Liabilities
Accounts payable	16.8	27.2	26.2	22.1	19.4	23.7
Payable/accrued	–	–	–	–	–	–
Accrued expenses	121	117	113	96.1	94.2	87.1
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	–	–	–	–	0	1.0
Other current liabilities	11.7	11.2	5.8	12.9	4.2	32.1
Total current liabilities	149	156	145	131	118	144
Long-term debt	121	218	124	132	221	194
Minority interest	–	–	–	–	–	–
Other liabilities	81.6	67.8	48.5	41.5	34.6	36.1
Total liabilities	352	442	318	304	373	374
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0	0	0	0	0	0
Additional paid-in capital	613	594	404	393	380	369
Retained earnings (accumulated deficit)	472	376	303	240	194	149
Treasury stock	–	–	–	–	–	–
Other equity	0	0	0	0	0	0
Total equity	1,085	970	707	634	574	519
Total liabilities & shareholders' equity	1,437	1,413	1,024	938	948	893

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Addus Homecare Corp, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	95.9	73.6	62.5	46.0	45.1	33.1
Depreciation, depletion & amortization	16.4	13.5	14.1	14.1	14.5	12.1
Deferred taxes	17.9	13.2	2.8	3.9	7.3	−4.7
Non-cash items	19.3	14.6	11.9	13.3	11.2	8.9
Changes in working capital	−38.0	1.5	20.9	27.8	−38.6	60.0
Cash from operations	112	116	112	105	39.5	109
Investing activities
Capital expenditures	−7.7	−6.0	−9.5	−8.3	−4.6	−6.8
Other investing cash flows	−24.8	−349	−110	−98.3	−37.4	−207
Cash from investing	−32.5	−355	−119	−107	−42.0	−214
Financing activities
Financing cash flow items	2.4	0	0.3	2.5	−1.9	3.9
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−98.7	272	−8.5	−90.0	28.3	134
Cash from financing	−96.3	272	−8.2	−87.5	26.3	138
Foreign exchange effects	–	–	–	–	–	–
Net change in cash	−17.3	34.1	−15.2	−88.9	23.8	33.4
Free cash flow	104	110	103	96.8	34.8	103

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.